Sign in

You're signed outSign in or to get full access.

Robin LaChapelle

Chief Operating Officer at ArriVent BioPharma
Executive

About Robin LaChapelle

Robin LaChapelle (age 52) is a co-founder of ArriVent BioPharma and serves as Chief Operating Officer (since Aug 7, 2023), after serving as Chief Administrative Officer (since Jun 1, 2021). She holds a B.A. in Psychology from Indiana University, Bloomington, and an M.A. in Psychology from Loyola University Chicago. Her cash incentives are tied to corporate and individual objectives (e.g., pipeline development, financial and strategic goals) as determined by the board; equity is delivered primarily via stock options with a standard four-year vesting schedule (25% cliff, monthly thereafter), aligning pay with long-term value creation .

Past Roles

OrganizationRoleYearsStrategic Impact
RLT Consulting (HR consulting firm)Executive DirectorJul 2019 – May 2021Leadership of HR consulting engagements
AstraZeneca plcVice President, Human RelationsMay 2015 – Jun 2019Oversaw a team of 50+ employees

External Roles

OrganizationRoleYearsNotes
PayPal Digital (subsidiary of PayPal, Inc.)DirectorCurrent (as of Apr 28, 2025)External directorship disclosed in AVBP proxy

Fixed Compensation

  • Latest disclosed base salary: $423,125 effective Feb 1, 2024; target annual bonus 40% of salary .
  • Prior base salary progression: $262,500 initial (reduced schedule, 2021 offer); $406,851 effective Feb 1, 2023 .
YearSalary ($)All Other Comp ($)Notes
2022319,16410,858Includes 401(k) match as “All Other Compensation”
2023392,63913,200Includes 401(k) match as “All Other Compensation”

Performance Compensation

  • Annual cash incentive plan: targets set as % of salary; assessment against corporate and individual goals (pipeline, financial, strategic), as determined by the board .
ComponentMetric(s)TargetActualPayout TimingVesting
Annual Cash Incentive (2022)Corporate/individual objectives40% of salary$127,667Paid in 2023N/A
Annual Cash Incentive (2023)Corporate/individual objectives40% of salary$180,614Paid Feb 2024N/A
Stock Options (see table)Time-based vestingN/AGrant-date fair value shown in SCTN/A4-year; 25% after 1 yr; monthly thereafter

Option grant history and vesting (time-based):

Grant DateOptions Granted (#)Vesting ScheduleNotes
Feb 1, 202243,72025% after 1 year; remainder monthly over 36 monthsStandard NEO schedule
Feb 1, 202331,22925% after 1 year; remainder monthly over 36 months
Aug 22, 202359,17125% after 1 year; remainder monthly over 36 months
Jan 1, 202449,30925% after 1 year; remainder monthly over 36 months

Note: An earlier S-1 (Jan 5, 2024) reflected larger pre-IPO option counts; subsequent S-1/A and the 2023 Form 10-K reflect adjusted grant share counts shown above .

Equity Ownership & Alignment

  • Founder Shares: 72,248 issued under a Founder Share Restriction Agreement dated May 13, 2021 .
  • Beneficial ownership (as of Apr 21, 2025): 124,583 shares common; 57,786 options exercisable or vesting within 60 days. Percent of outstanding ≈ 0.54% (182,369 ÷ 34,045,193) .
  • Hedging/pledging: Company insider trading policy prohibits short sales, margin/pledging, and hedging transactions (applies to executives and directors) .
Ownership DetailAmountAs-of DateSource
Common shares owned124,583Apr 21, 2025
Options exercisable/vesting within 60 days57,786Apr 21, 2025
Beneficial ownership (common + 60-day options)182,369Apr 21, 2025Calculated from
Shares outstanding (denominator)34,045,193Apr 21, 2025
Ownership % of outstanding~0.54%Apr 21, 2025Calculated from
Founder shares (issued)72,248May 13, 2021
Hedging/pledging policyProhibitedPolicy in effect

Employment Terms

  • Offer letter date (CAO role): May 21, 2021; at-will employment; confidentiality and conflict-of-interest covenants (e.g., no use of third-party confidential information) .
  • Executive Severance Plan: participant with the following terms (double-trigger equity acceleration on qualifying termination during Change-in-Control period) :
ScenarioCash SeveranceBonus TreatmentBenefits (COBRA)Equity
Termination without Cause (non-CIC period)1.25x base salary + pro-rated target bonusPro-rated target for year of terminationCompany-paid premiums up to 15 monthsNo acceleration disclosed outside CIC
CIC Termination (without Cause or for Good Reason during CIC period)1.5x base salary + target bonus (lump sum)Additional full-year target bonusCompany-paid premiums up to 18 monthsFull vesting of unvested equity; option exercise window extended to 1-year post-termination
Good Reason (definition excerpt)Material cut in pay/bonus opportunity, material diminution in title/duties/benefits, >35-mile relocation, or failure of successor to assume plan
CIC (definition excerpt)>50% change in voting power, sale of substantially all assets, certain mergers, or board turnover triggers, subject to 409A definitions

Investment Implications

  • Alignment: High equity leverage (multiple option grants, standard 4-year vesting) and founder shares create long-term alignment; anti-hedging/pledging policy mitigates misalignment risk .
  • Retention and supply: Ongoing monthly vesting across four option grants implies a steady stream of potentially saleable shares post-vesting; double-trigger acceleration in a CIC could increase float supply upon a transaction-related exit .
  • Cash incentive design: Target bonus set at 40% of salary with payouts tied to pipeline, financial and strategic milestones supports pay-for-performance, though specific weighting thresholds are not disclosed (governance relies on board discretion) .
  • Downside protection: Severance plan provides 1.25x cash protection outside CIC and 1.5x in CIC with full equity acceleration, balancing retention with shareholder sensitivities (no tax gross-up disclosed) .

Appendix: Additional Disclosures Supporting This Profile

  • Executive status and biography: COO since Aug 7, 2023; CAO since Jun 1, 2021; education; co-founder .
  • Compensation history (SCT, 2022–2023): Salary $319,164 (2022), $392,639 (2023); Option Awards $73,648 (2022), $374,533 (2023); Non-Equity Incentive $127,667 (2022), $180,614 (2023); All Other Comp $10,858 (2022), $13,200 (2023) .
  • Beneficial ownership details as of Apr 21, 2025 (proxy footnote and share count): 124,583 common; 57,786 options within 60 days; 34,045,193 shares outstanding .